Protect Your Body Against Today's Toxic Deluge
By Philip Domenico, PhD and Carey Monserrate
Nearly 70,000 industrial chemicals1 may now be found in everyday products, with 1,000 new synthetic chemicals introduced each year.2 Only a fraction of these have been tested for safety in humans.
EPA estimates indicate that average Americans may be carrying approximately 700 industrial chemicals in their bodies.3
In a Centers for Disease Control report, results from screenings of 2,500 Americans for 148 industrial chemicals were released.4 The startling findings reveal significant quantities of these chemicals were found in the bloodstreams of every individual tested.
As the body’s primary detoxifier, your liver serves as the frontline defense against chemical agents. Extracts from the milk thistle plant are among the most potent defenders of liver function. They are capable of halting and even reversing externally induced liver damage.
In this article, you will discover recent data underscoring milk thistle’s unique power to defend the liver against the effects of known toxins. You will also learn of research supporting its preventive effects against age-related diseases, including atherosclerosis, cancer, neurodegenerative disease, and diabetes.5-8
The liver performs over 300 critical metabolic functions. It is your body’s primary metabolic processor for virtually all substances, including those that are internally produced, like protein and cholesterol, and externally introduced substances like drugs and alcohol. Its central role in transforming or eliminating these chemicals makes the liver especially susceptible to chemically induced injury.
In addition to overexposure to thousands of synthetic chemicals in our post-industrial age,9 everyday drugs have been shown to dramatically increase the liver’s chemical burden. More than 900 drugs have been implicated in liver damage, including statins, hormonal contraceptives, and antibiotics like erythromycin.9 The popular pain-relieving drug Tylenol® (acetaminophen) happens to be the number one cause of acute liver failure in the United States.10
Many drugs require liver function monitoring to ensure no damage has been inflicted. Unfortunately, the damage inflicted by many liver toxins (also known as hepatotoxins) often goes undetected. This makes routine blood testing of vital importance, particularly if you’re taking a drug with potential hepatotoxic effects. Elevated liver enzymes in the blood indicate liver dysfunction, although liver damage can develop rapidly, before liver enzyme abnormalities manifest.
Silymarin, silibinin, and other milk thistle components protect against these and other chemical insults. They have been conclusively shown to counteract toxicity from a wide variety of toxic substances, including ethanol,11 organic solvents,12 pharmaceuticals,13,14 and mushroom-based poisons or mycotoxins.15,16 Milk thistle, for instance, produces superior survival rates from Amanita phalloides mushroom poisoning, compared with standard treatment.17
By altering liver cell membranes, silymarin inhibits toxin uptake and stimulates cell regeneration.18,19 Silymarin’s potent antioxidant activity helps to quell inflammation and replenish glutathione.18 Glutathione is the chief antioxidant inside most living cells and is the main line of defense against free radical damage. It is found in high concentrations in the liver.
Human studies are equally confirmatory. Silymarin treatment has been shown to significantly reduce liver-related mortality in patients with alcoholic liver damage.17,20 Clinical evidence supports silibinin for alcohol-induced cirrhosis.16,21 Silymarin reduced the symptoms of biliary retention caused by acute hepatitis of various causes in humans.22
In a review of viral hepatitis studies, silymarin decreased liver enzymes known as serum transaminases23 and improved symptoms and general well-being.24 Regarding activity against hepatitis C virus, silymarin and its components were anti-inflammatory. All compounds blocked virus-induced oxidative stress. Multiple assays suggest that numerous milk thistle compounds may help ameliorate hepatitis C disease.25
A high-carbohydrate diet can cause excess blood triglycerides to lodge in hepatic cells, causing inflammation and oxidative damage.26-28 This in turn results in nonalcoholic fatty liver disease or NAFLD, a condition that afflicts roughly one-third of all Americans.29
Left unchecked, NAFLD can progress to cirrhosis, carcinoma, and death. Clinical trials investigating silymarin showed significant reduction in liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), with no serious side effects.29 The authors concluded that this inexpensive and readily available extract should be considered an adjunct therapy in the treatment of NAFLD.
Milk thistle’s constituents, including silymarin, are powerful antioxidants.33 Beyond its utility as a liver tonic, milk thistle also protects against nerve damage and abnormal brain aging.
Silymarin helps protect certain cells of the central nervous system from free radical damage.34 It may also help protect against brain injury caused by stroke.35 Research in an animal model of dementia shows that silymarin reduces amyloid-beta deposition in the brain while improving behavior, a finding that suggests applications in preventing or slowing the progression of Alzheimer’s disease.8
Protection Against Cardiovascular Disease
Silymarin is also protective for those at high risk for cardiovascular disease. In animal models, silymarin’s antioxidant properties were shown to reduce oxidation of low-density lipoprotein (LDL)—a finding with important applications for protecting against cardiovascular health.36 Silymarin offers further atherosclerotic activity by inhibiting inflammation-induced adhesion molecule expression.37
Silymarin benefits lipid (fat) metabolism and protects against the ravages of overeating. Animals placed on a high-fat diet to induce hardening of the arteries (atherosclerosis) exhibited significant benefit from silymarin: reduced LDL, total cholesterol, triglycerides; and increased high-density lipoprotein (HDL) and glutathione.38,39
LDL and total cholesterol levels decreased in prostate cancer surgery patients who were administered silymarin (570 mg) with selenium (240 mcg).6
Fighting Metabolic Disorders
A 4-month clinical trial comprising 51 patients with type 2 diabetes showed that 200 mg of silymarin 3 times daily significantly lowered LDL, total cholesterol, and triglycerides, compared to placebo. It also lowered liver enzymes, fasting blood sugar, and hemoglobin A1c—a measure of long-term blood sugar control.5 In effect, silymarin may help your liver and your entire body cope with the trauma of excess food consumption. Benefits may also extend to diabetes5 and kidney injury.40
The chemopreventive role of silymarin has been established in laboratory and animal studies. Silymarin interferes with cancer growth and immortality, and it exhibits anti-inflammatory and anti-metastatic activity (prevents cancer spread). Furthermore, silymarin and silibinin may be valuable adjuncts to established anti-cancer therapies, to mitigate toxicity from chemotherapy or radiotherapy.7
Silibinin demonstrates efficacy against numerous malignancies including those of the liver, colon, skin, and prostate.41-45
Both topical and internally ingested silibinin extracts show promise against skin cancer. Silibinin displays photoprotection against the skin cancer-inducing effects of ultraviolet (UV) radiation through anti-inflammatory and anti-angiogenic effects.43 Silibinin may thus represent an important topical and internal agent for protecting the skin against the cancer-inducing effects of UV light.
Silibinin is an essential component for arresting replication of prostate cancer cells.41 Silibinin inhibited tumor growth, progression, local invasion, and distant metastasis of prostate cancer in mice. Research suggests that silibinin works in part by inducing cell cycle arrest.44
Among the milk thistle flavonolignans, isosilybin B proved to be the most effective at inhibiting prostate cancer cell growth and maintaining healthy prostate cell division.46,47 Isosilybin B suppressed a genetic factor in human cancers and was active against both hormone-dependent and hormone-independent prostate cancers in the laboratory.48 Isosilybin A and B together were effective suppressors of prostate-specific antigen (PSA) secretion, a marker of prostate cancer progression and recurrence.46
Together, these findings argue strongly for silibinin’s use as an adjunct to conventional chemotherapy.49
The liver is subjected to constant chemical assaults in the modern world. Over 70,000 industrial chemicals of unknown safety and 900 drugs known to induce liver damage underscore the critical need for optimal liver support. Milk thistle extracts protect and heal the liver from multiple forms of damage induced by foreign compounds, metabolic burdens, and infectious agents. Recent research indicates a role for silymarin, silibinin, and other milk thistle components in combating cancer, atherosclerosis, and neurodegenerative diseases like Alzheimer’s as well.
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at
1. Geiser K, Commoner B. Materials Matter: Toward a Sustainable Materials Policy. Cambridge, MA: The MIT Press; 2001.
2. U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics. Chemical Hazard Data Availability Study: What Do We Really Know About the Safety of High Production Volume Chemicals? Washington, D.C.: April 1998.
3. Onstot J, Ayling R, Stanley J. Characterization of HRGC/MSUnidentified Peaks from the Analysis of Human Adipose Tissue. Volume 1: Technical Approach. Washington, DC: U.S. Environmental Protection Agency Office of Toxic Substances; 1987.
4. Department of Health and Human Services. Third National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: Centers for Disease Control and Prevention; July 2005.
5. Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006 Dec;20(12):1036-9.
6. Vidlar A, Vostalova J, Ulrichova J, et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep;154(3):239-44
7. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008 Oct 8;269(2):352-62.
8. Murata N, Murakami K, Ozawa Y, et al. Silymarin attenuated the amyloid plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model. Biosci Biotechnol Biochem. 2010 Nov;74(11):2299-306.
9. Friedman SE, McQuaid KR, Grendell JH. Current Diagnosis and Treatment in Gastroenterology. New York: McGraw-Hill Medical; 2002.
10. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. Clin Gastroenterol. 2009 Apr;43(4):342-9.
11. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003 Oct;37(4):336-9.
12. Szilárd S, Szentgyörgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung. 1988;45(2):249-56.
13. Shaarawy SM, Tohamy AA, Elgendy SM, et al. Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. Int J Biol Sci. 2009 Aug;5(6):549-57.
14. Eminzade S, Uras F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond). 2008 Jul 5;5:18.
15. Jayaraj R, Deb U, Bhaskar AS, Prasad GB, Rao PV. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Envir Toxicol. 2007;22(5):472-9.
16. Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008 Feb;15(1):9-20.
17. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63.
18. Available at: http://www.medscape.com/viewarticle/422884. Accessed May 17, 2011.
19. Feher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2001 Apr 5.
20. Laekeman G, De Coster S, De Meyer K. St. Mary’s Thistle: an overview. J Pharm Belg. 2003;58(1):28-31.
21. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105-13.
22. El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009 May;16(5): 391-400.
23. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005 Nov;12(6):559-67.
24. Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004 Nov;36(11):752-9.
25. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA. 2010 Mar;107(13):5995-9.
26. York LW, Puthalapattu S, Wu GY. Nonalcoholic fatty liver disease and low-carbohydrate diets. Annu Rev Nutr. 2009;29:365-79.
27. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011 May;93(5):1048-52.
28. Kechagias S, Ernersson A, Dahlqvist O, et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotranferase in healthy subjects. Gut. 2008 May;57(5):649-54.
29. Hajaghamohammadi AA, Ziaee A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial. Hepatitis Monthly. 2008;8(3):191.
30. Burgess CA. Silybum marianum. J Pharmacol Soc Wisc. 2003 Mar-Apr:38-40.
31. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006 Nov;124(5):491-504.
32. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7.
33. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010 Oct;24(10):1423-32.
34. Tsai MJ, Liao JF, Lin DY, et al. Silymarin protects spinal cord and cortical cells against oxidative stress and lipopolysaccharide stimulation. Neurochem Int. 2010 Dec; 57(8):867-75.
35. Hou YC, Liou KT, Chern CM, et al. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-B and STAT-1 activation. Phytomedicine. 2010 Oct;17(2):963-73.
36. Wallace S, Vaughn K, Stewart BW, et al. Milk thistle extracts inhibit the oxidation of low-density lipoprotein (LDL) and subsequent scavenger receptor-dependent monocyte adhesion. J Agric Food Chem. 2008 Jun;56(11):3966-72.
37. Kang JS, Park SK, Yang KH, Kim HM. Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells. FEBS Lett. 2003 Aug;550(1-3):89-93.
38. Bialecka, M. The effect of bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits. Ann Acad Med Stetin. 1997 Jan;43:41-56.
39. Krecman V, Skottová N, Walterová D, Ulrichová J, Simánek V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med. 1998 Mar;64(2):138-42.
40. Sonnenbichler J, Scalera F, Sonnenbichler I, et al. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999 Sep;290(3):1375-83.
41. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. P21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007; 6(10):2696-707.
42. Ramasamy K, Dwyer-Nield LD, Serkova NJ, et al. Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res. 2011 Feb 15; 17(4):753-61.
43. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007;67:3483-91.
44. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007 Nov;143(1):58-65.
45. Cui W, Gu F, Hu K-Q. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol. 2009 Apr; 15(16):1943-50.
46. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005 May;65(10):4448-57.
47. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008 Jul;123(1):41-50.
48. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul;28(7):1533-42.
49. Greenlee H, Abascal K, Yarnell E, Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther. 2007 Jun;6(2):158-65.